Accelerating and de-risking CMC development with transposon-derived manufacturing cell lines.

Area of Science:

• Biotechnology
• Molecular Biology
• Cell Line Development

Background:

• Developing stable, high-producing cell lines is crucial for protein-based biologic drug manufacturing and Investigational New Drug (IND) filings.
• Traditional methods using nonhomologous recombination often face challenges like poor integration, genetic instability, and variable product quality.

Purpose of the Study:

• To introduce and evaluate the Leap-In Transposase platform, a novel transposon-based system for mammalian cell line development.
• To demonstrate the platform's ability to generate high-titer, genetically stable cell pools and clones.

Main Methods:

• Utilized the Leap-In Transposase system for gene integration in mammalian cells (e.g., Chinese hamster ovary cells).
• Assessed the productivity, genetic stability, and product quality of resulting cell pools and derived clones.

Main Results:

• The Leap-In Transposase platform consistently produced high-titer, stable cell pools.
• Derived clones showed productivity distributions strongly biased toward high producers.
• Demonstrated consistently high genetic and expression stability, surpassing nonhomologous recombination methods.

Conclusions:

• The Leap-In Transposase platform offers a robust solution for de-risking biologic drug development programs early.
• This system reduces timelines and resource requirements by overcoming limitations of traditional cell line development methods.